약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 4.

Table. 4.

Adverse events data

EMPA-REG OUTCOME6) EMEPEROR-Reduced7) EMEPEROR-Preserved8) EMPULSE34)
Empagliflozin Placebo Empagliflozin 10 mg Placebo Empagliflozin 10 mg Placebo Empagliflozin 10 mg Placebo
10 mg 25 mg
Any serious adverse event 37.4% 39% 42.3% 41.4% 48.1% 47.9% 51.6% 32.3% 43.6%
Volume depletion 4.9% 5.3% 4.9% 10.6% 9.9% - - - -
Acute renal failure 5.2% 5.3% 6.6% - - 12.1% 12.8% 7.7% 12.1%
Hypoglycemia 28% 27.6% 27.9% 1.4% 1.5% 2.4% 2.6% - -
Hypotension - - - 9.4% 8.7% 10.4% 8.6% - -
Ketoacidosis 0.1% <0.1% <0.1% 0% 0% 0.1% 0.2% 0% 0%
Urinary tract infections 18.2% 17.8% 18.1% 4.9% 4.5% 9.9% 8.1% 4.2% 6.4%
Genital infections 6.5% 6.3% 1.8% 1.7% 0.6% 2.2% 0.7% - -
Yakhak Hoeji 2022;66:175-83 https://doi.org/10.17480/psk.2022.66.4.175
© 2022 Yakhak Hoeji